The Human Tissue Authority has announced that its Chief Executive, Allan Marriott-Smith, will be stepping down at the end of 2021 after six years in the role.
Allan joined the HTA in May 2009, where he had corporate responsibility for strategic and business planning, quality improvement, and the regulation of living donation. He became Chief Executive in July 2015.
The HTA has experienced much change and growth during Allan’s tenure, including strengthening its collaborative working with partner organisations and increasing its engagement with members of the public.
Notable achievements under his leadership include a fundamental review of the HTA Codes of Practice and Standards, successfully completing a formal review of the HTA’s functions and significant improvements to the resilience and sustainability of the HTA’s regulatory systems and processes.
Commenting on the announcement, Allan said:
“Having worked at the HTA for twelve years, with six years as Chief Executive, I look forward to pursuing new leadership challenges in the health sector and beyond. I am committed to a smooth transition to a new Chief Executive to ensure that the HTA continues to fulfil its vital role in protecting public confidence and patient safety, which remains as important today as when the HTA was established.”
HTA Chair, Lynne Berry said:
“Allan has achieved an incredible amount in his six years as Chief Executive, including steering the HTA through a fundamental review of the Codes of Practice, guidance to practitioners to support deemed consent legislation for organ donation in Wales and England, and latterly in completing an office relocation to new premises in Stratford. I have very much enjoyed working with Allan and have been impressed by his commitment to patient safety and his concern for our values. The Board and I wish him every success in the future”.
Allan leaves the organisation towards the end of 2021, once a successor has been appointed.